Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERIFY-1 itepekimab in moderate-to-severe COPD
CTR20210843Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Aug 2021; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20210843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210843.